Reviewed listing: NASDAQ:OPRX · Analysis dated Oct 22, 2026
How does the company make money?
OptimizeRx helps pharmaceutical companies reach doctors and patients through digital health platforms. It is paid for advertising and information campaigns; the company does not develop its own drugs.
What supports the business?
Despite the revenue decline, cash remained from operations in the first half. The company reduced its loans and holds a small excess liquidity balance.
What could improve?
New platform offerings and higher customer budgets could improve earnings. However, the confirmed full-year outlook requires a significantly stronger second half.
How is the stock price assessed?
This assessment refers to the analysis and its quoted price shown here. It is not a live quote or a personal recommendation to buy.
9.37 USD looks expensive relative to cautiously normalized earnings. The mid-case model yields 6.31 USD per share; with a small margin of safety, the model-dependent limit is 6.00 USD.
What is the main risk?
Revenue from existing customers is declining. A small number of large pharmaceutical companies shape the business; fewer campaigns, privacy issues, or lost platform access would jeopardize the recovery.
What is the overall assessment?
Watch: OptimizeRx makes money from digital pharmaceutical advertising, but is losing revenue from existing customers. The share price assumes a recovery that is not yet visible in the reported figures.
Continue exploring this stock in your account
A free Marqora account gives you the detailed analysis with further evidence and lets you compare and save stocks. Your selected stock is kept when you sign in or register.
Open the full analysis in a free account →
Already have an account? Sign in